0NIQ Stock Chart & Stats
€195.80
-€3.80(-2.18%)
At close: 4:00 PM EDT
€195.80
-€3.80(-2.18%)
Day’s Range― - ―
52-Week Range€158.20 - €233.25
Previous CloseN/A
Volume31.00
Average Volume (3M)468.00
Market Cap
€17.89B
Enterprise Value€19.12B
Total Cash (Recent Filing)€230.70M
Total Debt (Recent Filing)€3.91B
Price to Earnings (P/E)92.0
Beta1.38
Next Earnings
Feb 23, 2027EPS Estimate
1.51Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)3.16
Shares Outstanding37,440,000
10 Day Avg. Volume308
30 Day Avg. Volume468
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.3
Revenue Forecast (FY)€3.73B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables DemandStrong recurring consumables growth supports revenue visibility because customers repurchase products as biopharmaceutical batches run and production scales. This installed-process exposure can deepen customer retention and provide a durable base that is less dependent on individual equipment orders.
Margin And Cash Flow ImprovementHigher volumes and operating leverage are translating into stronger profitability, while sharply higher free cash flow improves internal funding capacity. If sustained, this combination can support strategic investment, debt reduction, and resilience through normal fluctuations in customer spending.
Portfolio InnovationContinued product development broadens Sartorius's role across research and bioprocess workflows, including emerging AI-enabled laboratory use cases. Innovation can strengthen differentiation, increase customer switching costs, and create additional demand as biopharma customers seek faster, more productive processes.
Bears Say
Meaningful LeverageLeverage has improved but remains material, limiting financial flexibility relative to a lower-debt position. A sustained debt burden can constrain capital allocation and make the company more sensitive to weaker margins, slower demand, or the need to fund strategic investments.
Weak Cash ConversionPositive free cash flow is encouraging, but weak conversion from reported earnings indicates that cash realization remains less efficient than profitability alone suggests. Working-capital pressure, timing effects, or cash costs could reduce the funds available for debt repayment and reinvestment.
Cyclical Equipment DemandSartorius's equipment and non-recurring businesses depend on customer capacity plans and utilization, creating greater variability than consumables. This cyclicality can produce uneven order timing and make revenue and margin performance more vulnerable when biopharma customers defer capital projects.
Sartorius News
0NIQ FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest share price was €158.20 and its highest was €233.25 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €17.89B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Feb 23, 2027 which is in 117 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Oct 22, 2026. The company reported €1.27 earnings per share for the quarter, beating the consensus estimate of €1.251 by €0.019.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Overvalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.73 which represents an annual dividend yield of 0.32%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.51.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.27 in its last earnings report, beating expectations of €1.251. Following the earnings report the stock price went up 5.742%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in GB:0NIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.72%
12-Months-Change
Fundamentals
Return on Equity
6.92%
Trailing 12-Months
Asset Growth
0.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sartorius AG
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―